Letolizumab
In today's world, Letolizumab is a topic of great relevance and interest to a wide spectrum of society. As time has passed, Letolizumab has gained increasing importance in various fields, from politics to popular culture. In this article, we will thoroughly explore the impact and relevance of Letolizumab, analyzing its implications in everyday life, its evolution over the years and its influence in different areas of study. From its origins to the present, Letolizumab has been the subject of debate and reflection, and it is crucial to understand its importance in the current context. Therefore, it is essential to delve into this analysis to fully understand this topic that is so relevant today.
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized (from mouse) |
| Target | tumor necrosis factor-related activation protein |
| Clinical data | |
| Other names | BMS-986004 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1734H2688N466O538S10 |
| Molar mass | 38991.90 g·mol−1 |
Letolizumab (INN;[1] development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[2]
This drug was developed by Bristol-Myers Squibb.[3]
References
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- ^ Budamakuntla L, Shree-Lakshmi HV, Bansal A, Venkatarayaraju SK (2019). "Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India". Psoriasis: Targets and Therapy. 9: 19–27. doi:10.2147/PTT.S154073. PMC 6501705. PMID 31119094.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |